{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:22Z","timestamp":1784822602804,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00967-3","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:34:43Z","timestamp":1780688083000},"page":"1903-1915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Switch Rates, and Healthcare Costs of Botulinum Toxin Type\u00a0A Among Patients with Cervical Dystonia in the USA: A Retrospective Claims Analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Ning","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliza","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaji R.","family":"Manthena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshini","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"967_CR1","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2165\/00003495-200161130-00004","volume":"61","author":"M Velickovic","year":"2001","unstructured":"Velickovic M, Benabou R, Brin MF. Cervical dystonia. Drugs. 2001;61:1921\u201343. https:\/\/doi.org\/10.2165\/00003495-200161130-00004.","journal-title":"Drugs"},{"key":"967_CR2","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/wnl.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86:1818\u201326. https:\/\/doi.org\/10.1212\/wnl.0000000000002560.","journal-title":"Neurology"},{"key":"967_CR3","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/mds.25244","volume":"27","author":"TD Steeves","year":"2012","unstructured":"Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta\u2010analysis. Mov Disord. 2012;27:1789\u201396. https:\/\/doi.org\/10.1002\/mds.25244.","journal-title":"Mov Disord"},{"key":"967_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.parkreldis.2007.02.005","volume":"13","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007;13:411\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2007.02.005.","journal-title":"Parkinsonism Relat Disord"},{"key":"967_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144663","volume":"12","author":"R Maione","year":"2023","unstructured":"Maione R, Formica C, Quartarone A, Buono VL. The impact of non-motor symptoms on quality of life in cervical dystonia. J Clin Med. 2023;12:4663. https:\/\/doi.org\/10.3390\/jcm12144663.","journal-title":"J Clin Med"},{"key":"967_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/mds.10127","volume":"17","author":"L Camfield","year":"2002","unstructured":"Camfield L, Ben\u2010Shlomo Y, Warner TT, Epidemiological Study of Dystonia in Europe Collaborative Group. Impact of cervical dystonia on quality of life. Mov Disord. 2002;17:838\u201341. https:\/\/doi.org\/10.1002\/mds.10127.","journal-title":"Mov Disord"},{"key":"967_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s13760-025-02742-x","volume":"125","author":"H Elshebawy","year":"2025","unstructured":"Elshebawy H, Ramzy GM, Salama M, El-Jaafary S. Assessment of quality of life in patients with cervical dystonia and hemifacial spasm after botulinum toxin injections. Acta Neurol Belg. 2025;125:707\u201316. https:\/\/doi.org\/10.1007\/s13760-025-02742-x.","journal-title":"Acta Neurol Belg"},{"key":"967_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00035","volume":"8","author":"MF Contarino","year":"2017","unstructured":"Contarino MF, Dool JVD, Balash Y, et al. Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin. Front Neurol. 2017;8:35. https:\/\/doi.org\/10.3389\/fneur.2017.00035.","journal-title":"Front Neurol"},{"key":"967_CR9","unstructured":"Botox Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5236lbl.pdf. Accessed 2 Sept 2025."},{"key":"967_CR10","unstructured":"AbobotulinumtoxinA Prescribing Information. https:\/\/www.dysportusa.com\/PI. Accessed 2 Sept 2025."},{"key":"967_CR11","unstructured":"IncobotulinumtoxinA Prescribing Information. https:\/\/www.xeominaesthetic.com\/wp-content\/uploads\/2024\/07\/xeomin-pi-med-guide.pdf. Accessed 2 Sept 2025."},{"key":"967_CR12","unstructured":"DAXXIFY Prescribing Information. https:\/\/us-east-1-shared-usea1-02.graphassets.com\/cm8ni4ne705uv07lgcx664ldf\/oyjzJ0e5Qcu5juT5RcZK. Accessed 24 Oct 2025."},{"key":"967_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8030065","volume":"8","author":"F Scaglione","year":"2016","unstructured":"Scaglione F. Conversion ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in clinical practice. Toxins Basel. 2016;8:65. https:\/\/doi.org\/10.3390\/toxins8030065.","journal-title":"Toxins Basel"},{"key":"967_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mds.20403","volume":"20","author":"D Truong","year":"2005","unstructured":"Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type\u00a0A toxin (Dysport) in cervical dystonia: results of the first US randomized, double\u2010blind, placebo\u2010controlled study. Mov Disord. 2005;20:783\u201391. https:\/\/doi.org\/10.1002\/mds.20403.","journal-title":"Mov Disord"},{"key":"967_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd003633.pub3","volume":"12","author":"M Castel\u00e3oa","year":"2017","unstructured":"Castel\u00e3oa M, Marquesa RE, Duartea GS, et al. Botulinum toxin type\u00a0A therapy for cervical dystonia. Cochrane Database Syst Rev. 2017;12:CD003633. https:\/\/doi.org\/10.1002\/14651858.cd003633.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"967_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenk\u00e4mper","year":"2006","unstructured":"Roggenk\u00e4mper P, Jost WH, Bihari K, Comes G, Grafe S, NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type\u00a0A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303\u201312. https:\/\/doi.org\/10.1007\/s00702-005-0323-3.","journal-title":"J Neural Transm"},{"key":"967_CR17","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/mds.26760","volume":"31","author":"W Poewe","year":"2016","unstructured":"Poewe W, Burbaud P, Castelnovo G, et al. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized\u2010controlled trial. Mov Disord. 2016;31:1649\u201357. https:\/\/doi.org\/10.1002\/mds.26760.","journal-title":"Mov Disord"},{"key":"967_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/ene.13800","volume":"26","author":"M Simonetta\u2010Moreau","year":"2019","unstructured":"Simonetta\u2010Moreau M, Picaut P, Volteau M, Poewe W. Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport\u00ae). Eur J Neurol. 2019;26:943-e65. https:\/\/doi.org\/10.1111\/ene.13800.","journal-title":"Eur J Neurol"},{"key":"967_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.toxicon.2017.09.004","volume":"147","author":"HA Jinnah","year":"2018","unstructured":"Jinnah HA, Comella CL, Perlmutter J, Lungu C, Hallett M, Dystonia Coalition Investigators. Longitudinal studies of botulinum toxin in cervical dystonia: why do patients discontinue therapy? Toxicon. 2018;147:89\u201395. https:\/\/doi.org\/10.1016\/j.toxicon.2017.09.004.","journal-title":"Toxicon"},{"key":"967_CR20","doi-asserted-by":"crossref","unstructured":"Gratie D,\nMercer\nDW, Lee\nJH, Gillard P. Real-world botulinum toxin type\u00a0A treatment patterns in patients with cervical dystonia. Presented at AAMM 22-A 1 2022; Chicago, IL, USA; 2022.","DOI":"10.1016\/j.toxicon.2021.11.057"},{"key":"967_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1017\/cjn.2020.275","volume":"48","author":"M Petitclerc","year":"2021","unstructured":"Petitclerc M, Cloutier M, Naud P, Langlois M, Bhogal M, Davidovic G. Improvement in quality of life with onabotulinumtoxinA for cervical dystonia: POSTURe. Can J Neurol Sci. 2021;48:676\u201384. https:\/\/doi.org\/10.1017\/cjn.2020.275.","journal-title":"Can J Neurol Sci"},{"key":"967_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2024.107386","volume":"237","author":"K Dashtipour","year":"2024","unstructured":"Dashtipour K, Sadeghi M, Heath M, et al. Persistence, health care resource utilization, and costs among onabotulinumtoxinA-treated patients with cervical dystonia in the US. Toxicon. 2024;237:107386. https:\/\/doi.org\/10.1016\/j.toxicon.2024.107386.","journal-title":"Toxicon"},{"key":"967_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2025.108712","volume":"271","author":"D Charles","year":"2026","unstructured":"Charles D, Venditti L, Nelson M, et al. Physician assessment of non-medical toxin switching on patient care. Toxicon. 2026;271:108712. https:\/\/doi.org\/10.1016\/j.toxicon.2025.108712.","journal-title":"Toxicon"},{"key":"967_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2025.108711","author":"D Charles","year":"2026","unstructured":"Charles D, Venditti L, Nelson M, et al. Patient perspectives on nonmedical toxin switching and care. Toxicon. 2026. https:\/\/doi.org\/10.1016\/j.toxicon.2025.108711.","journal-title":"Toxicon"},{"key":"967_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14010044","volume":"14","author":"H Hefter","year":"2022","unstructured":"Hefter H, \u00dcrer B, Brauns R, et al. Significant long-lasting improvement after switch to incobotulinum toxin in cervical dystonia patients with secondary treatment failure. Toxins Basel. 2022;14:44. https:\/\/doi.org\/10.3390\/toxins14010044.","journal-title":"Toxins Basel"},{"key":"967_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2340\/16501977-1895","volume":"47","author":"DG Grosset","year":"2015","unstructured":"Grosset DG, Tyrrell EG, Grosset KA. Switch from abobotulinumtoxinA (Dysport\u00ae) to incobotulinumtoxinA (Xeomin\u00ae) botulinum toxin formulation: a review of 257 cases. J Rehabil Med. 2015;47:183\u20136. https:\/\/doi.org\/10.2340\/16501977-1895.","journal-title":"J Rehabil Med"},{"key":"967_CR27","unstructured":"U.S. Bureau of Labor Statistics Consumer Price Index. https:\/\/www.bls.gov\/cpi\/. Accessed 20 Jan 2026."},{"key":"967_CR28","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1007\/s12325-023-02563-5","volume":"40","author":"M Hull","year":"2023","unstructured":"Hull M, Anupindi VR, DeKoven M, He J, Bouchard J. Botulinum toxin utilization, treatment patterns, and healthcare costs among patients with spasticity or cervical dystonia in the US. Adv Ther. 2023;40:3986\u20134003. https:\/\/doi.org\/10.1007\/s12325-023-02563-5.","journal-title":"Adv Ther"},{"key":"967_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.98.18_supplement.1670","author":"D Gratie","year":"2022","unstructured":"Gratie D, Mercer DW, Lee JH, Gillard P. Real-world botulinum toxin type\u00a0A treatment patterns in patients with cervical dystonia (P17-11.005). Neurology. 2022. https:\/\/doi.org\/10.1212\/wnl.98.18_supplement.1670.","journal-title":"Neurology"},{"key":"967_CR30","first-page":"205","volume":"13","author":"VK Karschney","year":"2020","unstructured":"Karschney VK, Greeley DR. A retrospective cost analysis of patients who switched from onabotulinumtoxinA to incobotulinumtoxinA in a private neurology practice. Am Health Drug Benefits. 2020;13:205\u201310.","journal-title":"Am Health Drug Benefits"},{"key":"967_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.18553\/jmcp.2023.22205","volume":"30","author":"M Hull","year":"2023","unstructured":"Hull M, Danchenko N, Anupindi VR, DeKoven M, He J, Bouchard J. Health care resource utilization and costs among patients with spasticity or cervical dystonia. J Manag Care Spec Pharm. 2023;30:86\u201397. https:\/\/doi.org\/10.18553\/jmcp.2023.22205.","journal-title":"J Manag Care Spec Pharm"},{"key":"967_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5603\/pjnns.a2021.0005","volume":"55","author":"WH Jost","year":"2021","unstructured":"Jost WH, Dru\u017cd\u017c A, Pandey S, et al. Dose per muscle in cervical dystonia: pooled data from seven movement disorder centres. Neurol Neurochir Pol. 2021;55:174\u20138. https:\/\/doi.org\/10.5603\/pjnns.a2021.0005.","journal-title":"Neurol Neurochir Pol"},{"key":"967_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13070488","volume":"13","author":"R Kent","year":"2021","unstructured":"Kent R, Robertson A, Aguilar SQ, Tzoulis C, Maltman J. Real-world dosing of onabotulinumtoxinA and incobotulinumtoxinA for cervical dystonia and blepharospasm: results from TRUDOSE and TRUDOSE II. Toxins Basel. 2021;13:488. https:\/\/doi.org\/10.3390\/toxins13070488.","journal-title":"Toxins Basel"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00967-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:22Z","timestamp":1784819482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00967-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00967-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ning Cheng, Annaliza Dominguez, and Shivaji R Manthena, are employees of AbbVie and may hold AbbVie stock. Darshini Shah is a former employee of AbbVie and may hold AbbVie stock. She is no longer employed by AbbVie. She is an employee of Axsome Therapeutics Inc., New York, NY, USA and may hold Axsome Therapeutics Inc. stock.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The article does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}